Supplemental Online Content

Chen C, Wu S, Chen J, et al. Evaluation of the association of platelet count, mean platelet volume, and platelet transfusion with intraventricular hemorrhage and death among preterm infants. *JAMA Netw Open.* 2022;5(10):e2237588. doi:10.1001/jamanetworkopen.2022.37588

**eTable 1.** Distribution of Total Platelet Transfusion Number During Hospital Stay

**eTable 2.** Association of Platelet Transfusion, Platelet Count, and Mean Platelet Volume With Risk of IVH and In-Hospital Mortality: Full Results

**eTable 3.** Association Between Platelet Transfusion, Thrombocytopenia, Mean Platelet Volume, and Risk of IVH and In-Hospital Mortality

**eTable 4.** Association of Platelet Transfusion, Platelet Count, Platelet Distribution Width, or Platelet–Large Cell Ratio With Risk of IVH and In-Hospital Mortality

**eTable 5.** Association Between Platelet Transfusion-Associated Outcomes and Platelet Count, With Hazard Ratios at Certain Platelet Count Levels

**eTable 6.** Association Between Platelet Transfusion–Associated Outcomes and Mean Platelet Volume, With Hazard Ratios at Certain Combinations of Platelet Count Levels and Mean Platelet Volume Levels

**eFigure 1.** Association Between Platelet Transfusion–Associated Outcomes and Platelet Count, Extended

**eFigure 2.** Association Between Platelet Transfusion–Associated Outcomes and Platelet Distribution Width

**eFigure 3.** Association Between Platelet Transfusion-Associated Outcomes and Platelet–Large Cell Ratio

**eFigure 4.** Survival Plots Grouped by Pretransfusion Platelet Count at a Cutoff of 25 × 10^9/μL

**eFigure 5.** Survival Plots Grouped by Pretransfusion Platelet Count at a Cutoff of 50 × 10^9/μL

**eFigure 6.** Flowchart of Selection of the Study Population

**eMethods.** Methods for Measuring Platelet Count and Mean Platelet Volumes and Reference Ranges

This supplemental material has been provided by the authors to give readers additional information about their work.
eTable 1. Distribution of Total Platelet Transfusion Number During Hospital Stay

| Total Platelet Transfusion number During Hospital Stay | No. of Infants (%) |
|-------------------------------------------------------|--------------------|
| 1                                                     | 63/94 (67)         |
| 2                                                     | 14/94 (15)         |
| 3                                                     | 7/94 (7)           |
| 4                                                     | 3/94 (3)           |
| 5                                                     | 2/94 (2)           |
| 6                                                     | 4/94 (4)           |
| 8                                                     | 1/94 (1)           |
| **Total**                                             | **94**             |
**eTable 2. Association of Platelet Transfusion, Platelet Count, and Mean Platelet Volume With Risk of IVH and In-Hospital Mortality: Full Results**

| Outcomes a | Covariates b | Model 2 c |  | Model 3 c |  |
|------------|--------------|-----------|---|-----------|---|
| Any Grade of IVH | Platelet transfusion | 1.11 (0.92-1.35) | .27 | 1.11 (0.92-1.34) | .28 |
|  | Platelet count, per 50 000/μL decrease | 1.12 (1.04-1.21) | .002 | 1.13 (1.05-1.22) | .001 |
|  | Mean platelet volume, per 1 μm$^3$ increase | NA | NA | 0.94 (0.82-1.09) | .41 |
|  | Sex (female vs. male) | 1.05 (0.81-1.35) | .71 | 1.03 (0.80-1.34) | .81 |
|  | Gestational age, wks. (28-31 vs. < 28) | 0.63 (0.42-0.94) | .02 | 0.63 (0.42-0.95) | .03 |
|  | Gestational age, wks. (32-33 vs. < 28) | 0.29 (0.15-0.54) | <.001 | 0.29 (0.15-0.54) | <.001 |
|  | Gestational age, wks. (34-36 vs. <28) | 0.43 (0.20-0.92) | .03 | 0.41 (0.19-0.88) | .02 |
|  | Weight at birth, g (1000-1499 vs. < 1000) | 0.94 (0.63-1.38) | .74 | 0.90 (0.61-1.34) | .62 |
|  | Weight at birth, g (1500-2499 vs. < 1000) | 0.68 (0.42-1.10) | .12 | 0.65 (0.40-1.06) | .05 |
|  | Weight at birth, g (2500-3999 vs. < 1000) | 0.47 (0.14-1.57) | .22 | 0.47 (0.14-1.60) | .23 |
|  | Cesarean delivery (no vs. yes) | 1.38 (1.02-1.87) | .04 | 1.36 (1.00-1.85) | .048 |
|  | Maternal preeclampsia (no vs. yes) | 1.16 (0.77-1.73) | .48 | 1.19 (0.79-1.80) | .41 |
|  | High-risk pregnancy (no vs. yes) | 0.81 (0.61-1.08) | .15 | 0.81 (0.61-1.08) | .14 |
|  | Congenital disorder (no vs. yes) | 1.54 (1.02-2.32) | .04 | 1.52 (1.00-2.63) | .049 |
|  | Singletons (no vs. yes) | 1.49 (1.12-1.97) | .006 | 1.48 (1.12-1.97) | .006 |
|  | Premature rupture of membrane (no vs. yes) | 1.39 (0.92-2.11) | .12 | 1.39 (0.92-2.11) | .12 |
|  | Apgar score ≤ 7 at 1, 5, or 10 min (no vs. yes) | 0.74 (0.57-0.95) | .02 | 0.75 (0.57-0.97) | .03 |
|  | Pregnancy induced hypertension (no vs. yes) | 0.95 (0.50-1.80) | .88 | 0.95 (0.50-1.79) | .88 |
|  | Antenatal glucocorticosteroids given (no vs. yes) | 0.93 (0.72-1.2) | .60 | 0.93 (0.72-1.20) | .58 |
|  | Intrauterine growth restriction (no vs. yes) | 1.73 (0.80-3.72) | .16 | 1.64 (0.74-3.62) | .22 |
|  | Ventilation (yes vs. no) | 0.52 (0.19-1.42) | .20 | 0.51 (0.19-1.41) | .20 |
|  | Sepsis/NEC (yes vs. no) | 1.35 (0.75-2.46) | .32 | 1.39 (0.77-2.53) | .28 |
| **Grade III or IV IVH** | Platelet transfusion | 1.28 (0.89-1.84) | .18 | 1.30 (0.90-1.88) | .16 |
|  | Platelet count, per 50 000/μL decrease | 1.17 (1.03-1.33) | .02 | 1.16 (1.02-1.32) | .02 |
|  | Mean platelet volume, per 1 μm$^3$ increase | NA | NA | 0.94 (0.73-1.22) | .66 |
|  | Sex (female vs. male) | 0.85 (0.53-1.35) | .49 | 0.82 (0.51-1.32) | .40 |
|  | Gestational age, wks. (28-31 vs. < 28) | 0.34 (0.16-0.70) | .004 | 0.33 (0.16-0.72) | .005 |
|  | Gestational age, wks. (32-33 vs. < 28) | 0.30 (0.09-0.99) | .048 | 0.30 (0.09-1.04) | .057 |
|  | Gestational age, wks. (34-36 vs. <28) | 0.90 (0.16-5.04) | .91 | 0.72 (0.11-4.77) | .73 |
|  | Weight at birth, g (1900-1499 vs. < 1000) | 0.65 (0.31-1.36) | .25 | 0.61 (0.28-1.33) | .22 |
|  | Weight at birth, g (1500-2499 vs. < 1000) | 0.18 (0.05-0.62) | .006 | 0.17 (0.05-0.60) | .006 |
|  | Weight at birth, g (2500-3999 vs. < 1000) | 0.08 (0.00-1.44) | .09 | 0.09 (0.00-1.92) | .12 |
|  | Cesarean delivery (no vs. yes) | 0.95 (0.53-1.68) | .85 | 0.92 (0.51-1.64) | .77 |
|  | Maternal preeclampsia (no vs. yes) | 2.78 (1.21-6.36) | .02 | 3.24 (1.27-8.26) | .01 |
|  | High-risk pregnancy (no vs. yes) | 1.08 (0.60-1.98) | .79 | 1.06 (0.57-1.95) | .86 |
|  | Congenital disorder (no vs. yes) | 1.41 (0.68-2.94) | .35 | 1.38 (0.66-2.89) | .40 |
|  | Singletons (no vs. yes) | 1.14 (0.63-2.09) | .66 | 1.14 (0.62-2.12) | .67 |
|  | Premature rupture of membrane (no vs. yes) | 1.17 (0.52-2.63) | .71 | 1.14 (0.50-2.63) | .75 |
|  | Apgar score ≤ 7 at 1, 5, or 10 min (no vs. yes) | 0.38 (0.23-0.62) | <.001 | 0.38 (0.23-0.64) | <.001 |
|  | Pregnancy induced hypertension (no vs. yes) | 1.3 (0.30-5.65) | .72 | 1.28 (0.29-5.59) | .74 |
|  | Antenatal glucocorticosteroids given (no vs. yes) | 0.76 (0.47-1.24) | .27 | 0.75 (0.45-1.24) | .26 |
|  | Intrauterine growth restriction (no vs. yes) | 1.24 (0.42-3.70) | .70 | 1.15 (0.38-3.44) | .81 |
|  | Ventilation (yes vs. no) | 0.54 (0.07-4.23) | .56 | 0.52 (0.07-4.13) | .54 |
|  | Sepsis/NEC (yes vs. no) | 0.71 (0.16-3.12) | .65 | 0.75 (0.17-3.35) | .71 |

© 2022 Chen C et al. JAMA Network Open.
| Outcomes                        | Covariates                          | Model 2<sup>c</sup> | Model 3<sup>c</sup> |
|--------------------------------|-------------------------------------|----------------------|----------------------|
|                                 |                                     | HR (95% CI)          | P value              |
| Gestational age, wks. (28-31 vs. < 28) |                                     | 1.20 (0.60-2.41)     | .61                  |
| Gestational age, wks. (32-33 vs. < 28) |                                     | 2.20 (0.76-6.40)     | .15                  |
| Gestational age, wks. (34-36 vs. <28) |                                     | 2.88 (0.81-10.19)    | .10                  |
| Weight at birth, g (1000-1499 vs. < 1000) |                                     | 0.49 (0.26-0.92)     | .03                  |
| Weight at birth, g (1500-2499 vs. < 1000) |                                     | 0.18 (0.07-0.46)     | <.001                |
| Weight at birth, g (2500-3999 vs. < 1000) |                                     | 0.27 (0.06-1.30)     | .10                  |
| Cesarean delivery (no vs. yes) |                                     | 0.68 (0.39-1.20)     | .18                  |
| Maternal preeclampsia (no vs. yes) |                                     | 2.13 (1.04-4.34)     | .04                  |
| High-risk pregnancy (no vs. yes) |                                     | 1.37 (0.78-2.42)     | .28                  |
| Congenital disorder (no vs. yes) |                                     | 0.89 (0.49-1.62)     | .70                  |
| Singletons (no vs. yes)         |                                     | 1.43 (0.84-2.43)     | .19                  |
| Premature rupture of membrane (no vs. yes) |                             | 1.42 (0.62-3.27)     | .41                  |
| Apgar score ≤ 7 at 1, 5, or 10 min (no vs. yes) |                           | 0.71 (0.43-1.15)     | .16                  |
| Pregnancy induced hypertension (no vs. yes) |                           | 8.58 (5.0-146.98)    | .14                  |
| Antenatal glucocorticosteroids given (no vs. yes) |                     | 1.81 (1.14-2.89)     | .01                  |
| Intrauterine growth restriction (no vs. yes) |                              | 2.38 (0.64-8.87)     | .20                  |
| Ventilation (yes vs. no)        |                                     | 0.16 (0.04-0.66)     | .01                  |
| Sepsis/NEC (yes vs. no)         |                                     | 0.38 (0.07-1.99)     | .25                  |

Abbreviations: IVH, intraventricular hemorrhage; HR, hazard ratio; NA, not applicable; NEC, necrotizing enterocolitis.

<sup>a</sup> For any grade of IVH and grade III or IV IVH outcomes, the Fine-Gray sub distribution hazard model was used to account for the competing risk of death. For in-hospital mortality outcome, Cox proportional hazards model was used. P values were calculated using corresponding models.

<sup>b</sup> The platelet transfusion was defined as the cumulative number of platelet transfusions received by an infant one day prior to the outcome event. The platelet count and mean platelet volume were defined as the most recent results at least one day prior to the outcome event. To convert mean platelet volume to fL, multiply by 1.

<sup>c</sup> In Model 2, platelet transfusion and platelet count were simultaneously included as time-varying variables. Additionally, infant sex, birthweight strata, gestational age strata, congenital disorder, singleton, any Apgar score ≤ 7 (1-min, 5-min, or 10-min Apgar), cesarean delivery, maternal preeclampsia, pregnancy-induced hypertension, antenatal steroids given, intrauterine distress, maternal High-risk pregnancy, and premature rupture of membrane were adjusted as time-constant covariates. First ventilation time after birth and the sepsis/necrotizing enterocolitis occurrence time were adjusted as time-varying covariates. In Model 3, mean platelet volume was added to Model 2 as a time-varying covariate.
# Table 3. Association Between Platelet Transfusion, Thrombocytopenia, Mean Platelet Volume, and Risk of IVH and In-Hospital Mortality

| Outcomes      | Exposures                  | Unadjusted Model c | Adjusted Models d | Model 2 | Model 3 |
|---------------|----------------------------|--------------------|-------------------|---------|---------|
| Any grade of IVH | Platelet transfusion      | 1.26 (1.04-1.54)  | .02               | 1.14 (0.96-1.37)  | .14     | 1.15 (0.96-1.38)  | .14     |
|               | Thrombocytopenia (yes vs. no) | 2.24 (1.69-2.97)  | <.001             | 1.73 (1.28-2.35)  | <.001   | 1.69 (1.24-2.31)  | <.001   |
|               | Mean platelet volume, per 1 μm³ increase | 1.15 (1.00-1.33)  | .054              | NA      | NA      | 0.96 (0.84-1.11)  | .62     |
| Grade III or IV IVH | Platelet transfusion      | 1.75 (1.28-2.41)  | <.001             | 1.33 (0.94-1.89)  | .11     | 1.35 (0.94-1.94)  | .10     |
|               | Thrombocytopenia (yes vs. no) | 3.82 (2.46-5.95)  | <.001             | 2.10 (1.24-3.56)  | .006    | 2.02 (1.18-3.46)  | .01     |
|               | Mean platelet volume, per 1 μm³ increase | 1.34 (1.04-1.73)  | .02               | NA      | NA      | 0.94 (0.73-1.23)  | .66     |
| In-hospital mortality | Platelet transfusion      | 2.35 (1.88-2.92)  | <.001             | 1.70 (1.32-2.20)  | <.001   | 1.73 (1.33-2.24)  | <.001   |
|               | Thrombocytopenia (yes vs. no) | 9.43 (5.92-15.15) | <.001             | 5.81 (3.44-9.80)  | <.001   | 6.45 (3.79-10.99) | <.001   |
|               | Mean platelet volume, per 1 μm³ increase | 1.20 (0.93-1.55)  | .17               | NA      | NA      | 0.83 (0.67-1.01)  | .06     |

Abbreviations: IVH, intraventricular hemorrhage; HR, hazard ratio; NA, not applicable.

c For any grade of IVH and grade III or IV IVH outcomes, the Fine-Gray subdistribution hazard model was used to account for the competing risk of death. For in-hospital mortality outcome, Cox proportional hazards model was used. P values were calculated using corresponding models.

d Platelet transfusion, thrombocytopenia, or mean platelet volume was separately included in Model 1 as the only time-varying variable.

© 2022 Chen C et al. JAMA Network Open.
eTable 4. Association of Platelet Transfusion, Platelet Count, Platelet Distribution Width, or Platelet–Large Cell Ratio With Risk of IVH and In-Hospital Mortality

| Outcomes a | Exposures b | Model 1 (Unadjusted) c | Model 2 (Adjusted) d |
|-----------|-------------|------------------------|---------------------|
|           |             | HR (95% CI)            | P Value c           | HR (95% CI)          | P Value e           |
| PDW       |             |                        |                     |                     |
| Any grade of IVH | Platelet transfusion | NA | NA | 1.11 (0.92-1.34) | .29 |
|           | Platelet count, per 50 000/μL decrease | NA | NA | 1.13 (1.05-1.22) | .001 |
|           | PDW, per % increase | 1.06 (1.01-1.11) | .03 |
| Grade III or IV IVH | Platelet transfusion | NA | NA | 1.31 (0.91-1.88) | .15 |
|           | Platelet count, per 50 000/μL decrease | NA | NA | 1.15 (1.01-1.31) | .04 |
|           | PDW, per % increase | 1.14 (1.07-1.22) | <.001 |
| In-hospital mortality | Platelet transfusion | NA | NA | 1.47 (1.13-1.92) | .004 |
|           | Platelet count, per 50 000/μL decrease | NA | NA | 1.75 (1.49-2.06) | <.001 |
|           | PDW, per % increase | 1.12 (1.05-1.20) | .001 |
| P-LCR     |             |                        |                     |                     |
| Any grade of IVH | Platelet transfusion | NA | NA | 1.11 (0.92-1.34) | .28 |
|           | Platelet count, per 50 000/μL decrease | NA | NA | 1.13 (1.05-1.22) | .001 |
|           | P-LCR, per % increase | 1.02 (1.00-1.04) | .06 |
| Grade III or IV IVH | Platelet transfusion | NA | NA | 1.31 (0.90-1.89) | .16 |
|           | Platelet count, per 50 000/μL decrease | NA | NA | 1.17 (1.03-1.33) | .02 |
|           | P-LCR, per % increase | 1.04 (1.00-1.08) | .03 |
| In-hospital mortality | Platelet transfusion | NA | NA | 1.49 (1.14-1.94) | .003 |
|           | Platelet count, per 50 000/μL decrease | NA | NA | 1.75 (1.49-2.05) | <.001 |
|           | P-LCR, per % increase | 1.03 (1.00-1.07) | .07 |

Abbreviations: IVH, intraventricular hemorrhage; HR, hazard ratio; NA, not applicable; PDW, platelet distribution width; P-LCR, platelet-large cell ratio.

a For any grade of IVH and grade III or IV IVH outcomes, the Fine-Gray sub distribution hazard model was used to account for the competing risk of death. For in-hospital mortality outcome, Cox proportional hazards model was used. P values were calculated using corresponding models.

b The platelet transfusion was defined as the cumulative number of platelet transfusions received by an infant one day prior to the outcome event. The platelet count, PDW, or P-LCR were defined as the most recent results at least one day prior to the outcome event. To convert PDW or P-LCR to proportion of 1.0, multiply by 0.01.

c PDW or P-LCR was separately included in Model 1 as the only time-varying variable.

d In Model 2, in addition to PDW or P-LCR, infant sex, birthweight strata, gestational age strata, congenital disorder, singleton, any Apgar score ≤ 7 (1-min, 5-min, or 10-min Apgar), cesarean delivery, maternal preeclampsia, pregnancy-induced hypertension, antenatal steroids given, intraparternal
distress, maternal High-risk pregnancy, and premature rupture of membrane were adjusted as time-constant covariates. First ventilation time after birth and the sepsis/necrotizing enterocolitis occurrence time were adjusted as time-varying covariates.
### eTable 5. Association Between Platelet Transfusion-Associated Outcomes and Platelet Count, With Hazard Ratios at Certain Platelet Count Levels

| Outcomes               | PCT=25 000/μL | PCT=50 000/μL | PCT=75 000/μL | PCT=100 000/μL | PCT=125 000/μL | PCT=150 000/μL |
|------------------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Any grade of IVH       | 0.90 (0.69-1.18) | 0.94 (0.74-1.20) | 0.98 (0.78-1.22) | 1.01 (0.82-1.25) | 1.05 (0.87-1.28) | 1.09 (0.91-1.32) |
| Grade III or IV IVH    | 1.09 (0.66-1.80) | 1.14 (0.71-1.82) | 1.19 (0.76-1.85) | 1.24 (0.81-1.89) | 1.29 (0.86-1.94) | 1.35 (0.91-2.00) |
| In-hospital mortality  | 1.20 (0.89-1.62) | 1.26 (0.96-1.67) | 1.33 (1.02-1.74) | 1.40 (1.08-1.82) | 1.48 (1.13-1.93) | 1.56 (1.18-2.05) |

Abbreviations: PCT, platelet count; HR, hazard ratio.

---

**a** For any grade of IVH and grade III or IV IVH outcomes, the Fine-Gray sub distribution hazard model was used to account for the competing risk of death. For in-hospital mortality outcome, Cox proportional hazards model was used. *P* values were calculated using corresponding models.

**b** In models of all three outcomes, the platelet count was included as a time-varying variable and was defined as the most recent test result at least one day prior to the outcome event. Interaction term between platelet count and platelet transfusion was included in all three models, so the hazard ratio represented risk change for every additional platelet transfusion at certain platelet count levels. Despite of linear term, quadratic term of platelet count was added to the model of any grade of IVH, and quadratic and cubic terms were added to the model of in-hospital mortality since they were statistically significant. In all three models, infant sex, birthweight strata, gestational age strata, congenital disorder, singleton, any Apgar score ≤ 7 (1-min, 5-min, or 10-min Apgar), cesarean delivery, maternal preeclampsia, pregnancy-induced hypertension, antenatal steroids given, intrauterine distress, maternal High-risk pregnancy, and premature rupture of membrane were adjusted as time-constant covariates; first ventilation time after birth and the sepsis/necrotizing enterocolitis occurrence time after birth were adjusted as time-varying covariates.
### eTable 6. Association Between Platelet Transfusion–Associated Outcomes and Mean Platelet Volume, With Hazard Ratios at Certain Combinations of Platelet Count Levels and Mean Platelet Volume Levels

| Outcomes a | MPV Level, μm b | PCT=25 000/μL | PCT=50 000/μL | PCT=75 000/μL | PCT=100 000/μL | PCT=125 000/μL | PCT=150 000/μL |
|------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Any grade of IVH | 10.0 | 0.79 (0.48-1.29) | 0.81 (0.51-1.28) | 0.83 (0.53-1.29) | 0.85 (0.55-1.31) | 0.87 (0.56-1.33) | 0.89 (0.58-1.37) |
| | 10.3 | 0.81 (0.52-1.25) | 0.83 (0.55-1.25) | 0.85 (0.57-1.26) | 0.87 (0.59-1.28) | 0.89 (0.60-1.31) | 0.91 (0.62-1.35) |
| | 10.8 | 0.84 (0.59-1.19) | 0.86 (0.61-1.20) | 0.88 (0.64-1.22) | 0.91 (0.66-1.25) | 0.93 (0.68-1.28) | 0.96 (0.69-1.32) |
| | 11.5 | 0.88 (0.67-1.16) | 0.90 (0.70-1.17) | 0.93 (0.73-1.20) | 0.96 (0.75-1.22) | 0.99 (0.78-1.26) | 1.02 (0.80-1.30) |
| Grade III or IV IVH | 12.2 | 0.92 (0.71-1.20) | 0.96 (0.75-1.22) | 0.99 (0.79-1.24) | 1.02 (0.82-1.27) | 1.05 (0.86-1.30) | 1.09 (0.89-1.34) |
| | 12.8 | 0.96 (0.91-1.31) | 1.00 (0.75-1.33) | 1.04 (0.80-1.35) | 1.07 (0.84-1.37) | 1.11 (0.88-1.40) | 1.15 (0.93-1.44) |
| | 13.1 | 0.99 (0.70-1.40) | 1.02 (0.74-1.41) | 1.06 (0.79-1.43) | 1.10 (0.84-1.45) | 1.14 (0.88-1.48) | 1.18 (0.93-1.51) |
| In-hospital Mortality | 10.0 | 1.13 (0.49-2.60) | 1.31 (0.62-2.77) | 1.51 (0.76-2.98) | 1.74 (0.93-3.26) | 2.01 (1.11-3.64) | 2.32 (1.29-4.18) |
| | 10.3 | 1.14 (0.53-2.44) | 1.29 (0.65-2.57) | 1.46 (0.78-2.73) | 1.66 (0.93-2.94) | 1.88 (1.09-3.23) | 2.12 (1.25-3.60) |
| | 10.8 | 1.16 (0.60-2.22) | 1.27 (0.70-2.30) | 1.39 (0.81-2.39) | 1.52 (0.92-2.51) | 1.67 (1.04-2.67) | 1.83 (1.17-2.87) |
| | 11.5 | 1.18 (0.69-2.02) | 1.24 (0.76-2.03) | 1.30 (0.82-2.05) | 1.36 (0.88-2.08) | 1.42 (0.94-2.14) | 1.48 (1.00-2.21) |
| | 12.2 | 1.21 (0.74-1.97) | 1.21 (0.76-1.90) | 1.21 (0.78-1.86) | 1.21 (0.79-1.83) | 1.21 (0.79-1.83) | 1.21 (0.78-1.86) |
| | 12.8 | 1.23 (0.73-2.08) | 1.18 (0.73-1.91) | 1.14 (0.72-1.80) | 1.09 (0.69-1.73) | 1.05 (0.65-1.70) | 1.01 (0.60-1.70) |
| | 13.1 | 1.24 (0.70-2.18) | 1.17 (0.70-1.95) | 1.10 (0.67-1.80) | 1.04 (0.63-1.70) | 0.98 (0.58-1.65) | 0.92 (0.52-1.65) |

Abbreviations: IVH, intraventricular hemorrhage; HR, hazard ratio; PCT, platelet count; MPV, mean platelet volume.

a For any grade of IVH and grade III or IV IVH outcomes, the Fine-Gray sub distribution hazard model was used to account for the competing risk of death. For in-hospital mortality outcome, Cox proportional hazards model was used. P values were calculated using corresponding models.

b Mean platelet volume of 10.0 μm³, 10.3 μm³, 10.8 μm³, 11.5 μm³, 12.2 μm³, 12.8 μm³, and 13.1 μm³ were selected because they are the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentile of the all mean platelet volume results of the study population.

c In all three models, the platelet count and mean platelet volume were included as time-varying variables and were defined as the most recent results at least one day prior to the outcome event. Two-way interaction terms between platelet count and platelet transfusion, between mean platelet volume and platelet transfusion, and three-way interaction term between platelet count, mean platelet volume, and platelet transfusion were included in all three models, so hazard ratio represented risk change for every additional platelet transfusion at certain platelet count and mean platelet volume levels. Despite of linear term, quadratic term of platelet count was added to the model of any grade of IVH, and quadratic and cubic terms were added to the model of in-hospital mortality since they were statistically significant. In all three models, infant sex, birthweight strata, gestational age strata, congenital disorder, singleton, any Apgar score ≤ 7 (1-min, 5-min, or 10-min Apgar), cesarean delivery, maternal preeclampsia, pregnancy-induced hypertension, antenatal steroids given, intrauterine distress, maternal High-risk pregnancy, and premature rupture of membrane were adjusted as time-constant covariates; first ventilation time after birth and the sepsis/necrotizing enterocolitis occurrence time after birth were adjusted as time-varying covariates.

© 2022 Chen C et al. JAMA Network Open.
eFigure 1. Association Between Platelet Transfusion–Associated Outcomes and Platelet Count, Extended

The dark line represents the hazard ratio, and the shaded area represents the 95% CI. Vertical dotted lines indicate platelet count values of 25,000 No./μL, 50,000 No./μL, 75,000 No./μL, 170,000 No./μL, 248,000 No./μL, 337,000 No./μL, and 505,000 No./μL. The last five values represented 5th, 25th, 50th, 75th, and 95th percentile of all platelet count results in the study sample. In panels A and B, hazard ratios were estimated by the Fine-Gray subdistribution hazard model to account for the competing risk of death. In panel C, the Cox proportional hazards model was used to estimate the hazard ratio. In three models, the platelet count was included as a time-varying variable, which was defined as its most recent result at least one day prior to the outcome event. The interaction term between platelet count and platelet transfusion was included in all three models, so the hazard ratio represents the risk change for every additional platelet transfusion at a certain platelet count level. Despite the linear term, the
quadratic term of platelet count was added to the model of any grade IVH, and quadratic and cubic terms were added to the model of in-hospital mortality since they were statistically significant. Additionally, in all three models, infant sex, birthweight strata, gestational age strata, congenital disorder, singleton, any Apgar score ≤ 7 (1-min, 5-min, or 10-min Apgar), cesarean delivery, maternal preeclampsia, pregnancy-induced hypertension, antenatal steroids given, intrauterine distress, maternal high-risk pregnancy, and premature rupture of membrane were adjusted as time-constant covariates; first ventilation time after birth and the sepsis/necrotizing enterocolitis occurrence time after birth were adjusted as time-varying covariates.
eFigure 2. Association Between Platelet Transfusion–Associated Outcomes and Platelet Distribution Width

A Any grade of IVH

Abbreviation: PCT, platelet count.

To convert platelet distribution width to proportion of 1.0, multiply by 0.01.

© 2022 Chen C et al. JAMA Network Open.
The dark line represents the hazard ratio, and the shaded area represents the 95% CI. Vertical dotted lines indicate the 5th, 25th, 50th, 75th, and 95th percentiles of platelet distribution width records in the whole sample. In panels A and B, hazard ratios were estimated by the Fine-Gray subdistribution hazard model to account for the competing risk of death. In panel C, the Cox proportional hazards model was used to estimate the hazard ratio. In three models, the platelet count and platelet distribution width were included as time-varying variables, which were defined as the most recent test result at least one day prior to the outcome event. Additionally, infant sex, birthweight strata, gestational age strata, congenital disorder, singleton birth, Apgar score ≤ 7 (1-min, 5-min, or 10-min Apgar), cesarean delivery, maternal preeclampsia, pregnancy-induced hypertension, antenatal steroid use, intrapartum distress, maternal high-risk pregnancy, and premature rupture of membrane were adjusted as time-constant covariates. First ventilation time after birth and the sepsis/necrotizing enterocolitis occurrence time after birth were adjusted as time-varying covariates. In addition, two-way interaction terms between platelet count and platelet transfusion, between platelet distribution width and platelet transfusion, and three-way interaction terms between platelet count, platelet distribution width, and platelet transfusion were included in all three models. Despite the linear term, the quadratic term of platelet count was added to the model of any grade IVH, and quadratic and cubic terms were added to the model of in-hospital mortality.
Abbreviation: PCT, platelet count.

To convert platelet-large cell ratio to proportion of 1.0, multiply by 0.01.
The dark line represents the hazard ratio, and the shaded area represents the 95% CI. Vertical dotted lines indicate the 5th, 25th, 50th, 75th, and 95th percentiles of platelet-large cell ratio records in the whole sample. In panels A and B, hazard ratios were estimated by the Fine-Gray subdistribution hazard model to account for the competing risk of death. In panel C, the Cox proportional hazards model was used to estimate the hazard ratio. In three models, the platelet count and platelet-large cell ratio were included as time-varying variables, which were defined as the most recent test result at least one day prior to the outcome event. Additionally, infant sex, birthweight strata, gestational age strata, congenital disorder, singleton birth, Apgar score ≤ 7 (1-min, 5-min, or 10-min Apgar), cesarean delivery, maternal preeclampsia, pregnancy-induced hypertension, antenatal steroid use, intrauterine distress, maternal high-risk pregnancy, and premature rupture of membrane were adjusted as time-constant covariates. First ventilation time after birth and the sepsis/necrotizing enterocolitis occurrence time after birth were adjusted as time-varying covariates. In addition, two-way interaction terms between platelet count and platelet transfusion, between platelet-large cell ratio and platelet transfusion, and three-way interaction terms between platelet count, platelet-large cell ratio, and platelet transfusion were included in all three models. Despite the linear term, the quadratic term of platelet count was added to the model of any grade IVH, and quadratic and cubic terms were added to the model of in-hospital mortality.
eFigure 4. Survival Plots Grouped by Pretransfusion Platelet Count at a Cutoff of 25 × 103/μL

Panel 1. For any grade IVH endpoint

Abbreviation: PCT, platelet count.

Neonates who received prophylactic transfusions (a transfusion that occurred before any grade of IVH) with PCT records within the 24 hours (1 day) prior to the transfusion were selected to ensure the timeliness of the PCT. If multiple PCT records existed within the 24 hours prior to the transfusion, the lowest value was selected. Kaplan-Meier method was applied to estimate the survival curve. Log-rank test was performed.
Panel 2. For Grade III and IV IVH endpoint

Product-Limit Survival Estimates
With Number of Subjects at Risk

+ Censored
Logrank p=0.0346

Survival Probability

Survival time (day)

| Group          | PCT < 25,000/μL | PCT ≥ 25,000/μL |
|----------------|-----------------|-----------------|
| PCT < 25,000/μL| 14              | 56              |
| PCT ≥ 25,000/μL| 12              | 32              |
|                | 11              | 26              |
|                | 8               | 21              |
|                | 7               | 13              |
|                | 2               | 4               |
|                | 0               | 0               |

Abbreviation: PCT, platelet count.

Neonates who received prophylactic transfusions (a transfusion that occurred before any grade of IVH) with PCT records within the 24 hours (1 day) prior to the transfusion were selected to ensure the timeliness of the PCT. If multiple PCT records existed within the 24 hours prior to the transfusion, the lowest value was selected. Kaplan-Meier method was applied to estimate the survival curve. Log-rank test was performed.
Panel 3. For survival endpoint

Product-Limit Survival Estimates
With Number of Subjects at Risk

| Group          | Survival Probability | Survival time (day) |
|----------------|----------------------|---------------------|
| PCT < 25 000/µL | 14                   | 56                  |
| PCT ≥ 25 000/µL | 37                   | 37                  |

Abbreviation: PCT, platelet count.

Neonates who received prophylactic transfusions (a transfusion that occurred before any grade of IVH) with PCT records within the 24 hours (1 day) prior to the transfusion were selected to ensure the timeliness of the PCT. If multiple PCT records existed within the 24 hours prior to the transfusion, the lowest value was selected. Kaplan-Meier method was applied to estimate the survival curve. Log-rank test was performed.
eFigure 5. Survival Plots Grouped by Pretransfusion Platelet Count at a Cutoff of 50 × 103/μL

Panel 1. For any grade IVH endpoint

Abbreviation: PCT, platelet count.

Neonates who received prophylactic transfusions (a transfusion that occurred before any grade of IVH) with PCT records within the 24 hours (1 day) prior to the transfusion were selected to ensure the timeliness of the PCT. If multiple PCT records existed within the 24 hours prior to the transfusion, the lowest value was selected. Kaplan-Meier method was applied to estimate the survival curve. Log-rank test was performed.
Panel 2. For Grade III and IV IVH endpoint

Product-Limit Survival Estimates
With Number of Subjects at Risk

Survival Probability

Survival time (day)

+ Censored
Logrank p=0.6685

| Group | PCT < 50,000/μL | PCT ≥ 50,000/μL |
|-------|----------------|-----------------|
|       | 49             | 21              |
|       | 31             | 13              |
|       | 25             | 12              |
|       | 19             | 10              |
|       | 14             | 6               |
|       | 5              | 1               |
|       | 0              | 0               |

Abbreviation: PCT, platelet count.

Neonates who received prophylactic transfusions (a transfusion that occurred before any grade of IVH) with PCT records within the 24 hours (1 day) prior to the transfusion were selected to ensure the timeliness of the PCT. If multiple PCT records existed within the 24 hours prior to the transfusion, the lowest value was selected. Kaplan-Meier method was applied to estimate the survival curve. Log-rank test was performed.
Panel 3. For survival endpoint

**Product-Limit Survival Estimates**

*With Number of Subjects at Risk*

[Graph showing survival probability over time with different groups: PCT < 50,000/µL and PCT ≥ 50,000/µL.]

| Group                  | Survival Probability |
|------------------------|----------------------|
| PCT < 50,000/µL        | 0.49                 |
|                        | 0.29                 |
|                        | 0.17                 |
|                        | 0.07                 |
|                        | 0.01                 |
| PCT ≥ 50,000/µL        | 0.80                 |
|                        | 0.79                 |
|                        | 0.78                 |
|                        | 0.77                 |
|                        | 0.76                 |

Abbreviation: PCT, platelet count.

Neonates who received prophylactic transfusions (a transfusion that occurred before any grade of IVH) with PCT records within the 24 hours (1 day) prior to the transfusion were selected to ensure the timeliness of the PCT. If multiple PCT records existed within the 24 hours prior to the transfusion, the lowest value was selected. Kaplan-Meier method was applied to estimate the survival curve. Log-rank test was performed.
eFigure 6. Flowchart of Selection of the Study Population

1562 infants were with complete perinatal records and received ventilation

341 were excluded
314 admitted after birthday
39 were term infants (GA >= 37)
12 were both term infants and admitted after birthday

1221 infants were included in the final analysis
eMethods. Methods for Measuring Platelet Count and Mean Platelet Volumes and Reference Ranges

In our institution, platelet count and mean platelet volume are determined by an automated hematology analyzer (xs800i; Sysmex, Japan) according to the manufacturer’s instructions. Briefly, blood cells wrapped by the sheath liquid pass one by one through a certain track within the detection region. Digital waveforms are originally recorded and transferred to physical parameters to depict the status of the platelet.

The normal reference range for the platelet count is 100 to 300×10⁹/L, and the mean platelet volume is 7.6 to 15 fL.